{"id":62064,"date":"2023-09-17T08:41:35","date_gmt":"2023-09-17T12:41:35","guid":{"rendered":"https:\/\/ifintechworld.com\/news\/hastens-325m-deal-for-china-rights-to-pcsk9-cholesterol-therapy\/"},"modified":"2023-09-17T08:41:40","modified_gmt":"2023-09-17T12:41:40","slug":"hastens-325m-deal-for-china-rights-to-pcsk9-cholesterol-therapy","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=62064","title":{"rendered":"Hasten&#8217;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy"},"content":{"rendered":"<div data-test-id=\"content-container\">\n<p><figure class=\"getty-figure\" data-type=\"getty-image\"><picture>  <\/picture><figcaption> <\/figcaption><\/figure>\n<\/p>\n<h2>Deals and Financings<\/h2>\n<p>Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering cholesterol from US-based LIB Therapeutics. Lerodalcibep is a next-gen PCSK9 inhibitor that may overcome the limitations of current<span class=\"paywall-full-content invisible\"> low-density lipoprotein products for patients at high-risk for cardiovascular disease. In a global Phase III trial, conducted in patients with difficult-to-treat disease, lerodalcibep reduced mean LDL-C in the intent-to-treat population by 58.6% at Week 24. Hasten will make an upfront payment of $20 million to LIB and be responsible for milestones of up to $305 million.<\/span><\/p>\n<p class=\"paywall-full-content invisible\">Insilico Medicine, a Hong Kong-New York AI drug discovery company, out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis (EXEL) of Alameda, California (see story). Exelixis will pay $80 million upfront plus unspecified milestones and<span class=\"paywall-full-content no-summary-bullets invisible\"> royalties. USP1 repairs DNA damage by removing ubiquitin from multiple substrates. Exelixis will also have rights to other Insilico-discovered USP1 candidates. Founded in 2018, Insilico has partnered with US and China biopharmas to discover candidates for specific targets, including a six-drug deal worth up to $1.2 billion with Sanofi (<\/span>SNY<span class=\"paywall-full-content no-summary-bullets invisible\">).<\/span><\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Suzhou Cure Genetics, a cell and gene therapy company, announced a $60 million deal to create AAV vectors for Hong Kong\u2019s Frametact, a neurodegenerative disease startup. Frametact was founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases. It targets familial diseases that include Alzheimer&#8217;s, Parkinson&#8217;s and Huntington&#8217;s disease. Cure, which will apply its VELP\u2122 platform to develop novel Adeno-Associated Virus (AAV) vectors, will receive $60 million in upfront and milestone payments, plus royalties on revenues.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Last week, Shanghai ImmuneOnco Biotech (HK: 01541) completed a $30 million IPO on the Hong Kong Stock Exchange to support its portfolio of oncology candidates that exploit innate and adaptive immunity. The company contrasts its portfolio with most other companies that stress adaptive immunity only, which it says causes low response rates and inevitable drug resistance. ImmuneOnco\u2019s lead product, IMM01, is a next-gen CD47-targeted molecule currently in China Phase II clinical trials. IMM01 is a recombinant human SIRP\u03b1 IgG1 fusion protein that simultaneously blocks a &#8220;don&#8217;t eat me&#8221; signal mediated by CD47\/SIRP\u03b1 and activates an &#8220;eat me&#8221; signal by interacting with Fc\u03b3Rs on macrophages.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Shanghai JW Therapeutics (OTCPK:JWCTF) will add two additional candidates for China to its T cell-based therapeutics collaboration with Boston\u2019s 2seventy bio (TSVT): a T-cell receptor molecule for solid tumors and a CAR T candidate for autoimmune diseases (see story). The collaboration, announced last year, was set up to advance 2seventy products into clinical trials quickly. One of the two original products, a MAGE-A4 solid tumor program, is expected to start an investigator study later this year, which is faster than expected. JW was formed by Wuxi Apptec (wixif) and Seattle\u2019s Juno Therapeutics to bring cell therapies to China.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Shanghai Pharmaceuticals (OTCPK:SHPMF) signed an MOU with Korea\u2019s AriBio to jointly conduct the China arm of a global Phase III trial of a therapy for mild Alzheimer\u2019s disease (see story). AriBio\u2019s AR1001 is a selective inhibitor of phosphodiesterase 5 (PDE5) that is designed to inhibit neuron apoptosis and restore synaptic plasticity. If the drug is approved, Shanghai Pharma will have distribution and manufacturing rights for the candidate in China. In a Phase II trial, AR1001 was safe, and it showed efficacy, especially if patients were not taking other Alzheimer&#8217;s medications, such as Aricept.<\/p>\n<h2 class=\"paywall-full-content invisible no-summary-bullets\">Trials and Approvals<\/h2>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Zhejiang BioRay Pharma was approved for a China launch of its Class I innovative therapeutic biological product, zuberitamab injection (Anruixi\u00ae), to treat CD20-positive diffuse large B-cell lymphoma. Anruixi is China&#8217;s first CD20 Class I mAb. It targets CD20 on the surface of B-cell, leading to B-cell elimination via ADCC and CDC. The company believes its product has a stronger ADCC effect than the competition. Anruixi is the first China-developed Class I anti-CD20 drug approved for China use and BioRay\u2019s sixth marketed product. BioRay is conducting trials of Anruixi for autoimmune diseases, including primary immune thrombocytopenia.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Shanghai Dizal Pharma (SHA: 688192) reported its NDA for golidocitinib was accepted by China\u2019s CDE for review as a treatment of relapsed or refractory peripheral T-cell lymphoma (r\/r PTCL). Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor that showed efficacy in a global, multicenter pivotal study. In a trial that enrolled 112 r\/r PTCL patients, golidocitinib produced an ORR of 44% and a CRR of 24%. One month ago, Dizal announced that its lead drug, sunvozertinib, was approved for China use as a second line therapy for NSCLC with EGFR exon 20 insertion mutations.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">San Diego\u2019s Sorrento Therapeutics (OTCPK:SRNEQ) reported positive topline results of a pivotal China Phase III trial of an oral Mpro inhibitor, Ovydso (olgotrelvir), a treatment for mild or moderate SARS-CoV-2 (see story). The candidate works by inhibiting the virus from entering cells. Ovydso met the trial\u2019s endpoints by lowering the time to sustained recovery of 11 COVID-19 symptoms: 8.6 days compared to 11.0 days in the placebo group. It also reduces the viral RNA copy load at Day 4 (after the three-day treatment). The trial enrolled 1,212 patients at 25 China sites.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Biosyngen, a Singapore-Guangzhou cell therapy company, was green-lighted to begin a US Phase I\/II clinical trial of its first T-cell receptor-engineered targeted (TCR-T) product for lung cancer, gastric cancer and other advanced solid tumors. The approval for BRL03 is the company&#8217;s third first-in-class therapy and its first self-developed candidate to start clinical trials. Biosyngen is currently filing an IND application for BST02, a tumor-infiltrating lymphocyte (TIL) molecule. When BRL03 is approved, the company will have clinical-stage assets in all three major T-cell therapy types &#8212; CAR-T, TCR-T and TIL. h<\/p>\n<hr class=\"paywall-full-content invisible no-summary-bullets\">\n<p class=\"paywall-full-content invisible no-summary-bullets\"><strong>Disclosure:<\/strong> none. <\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\"><strong><em>Original Post<\/em><\/strong><\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\"><strong>Editor&#8217;s Note:<\/strong> The summary bullets for this article were chosen by Seeking Alpha editors.<\/p>\n<p class=\"paywall-full-content invisible no-summary-bullets\">Editor&#8217;s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.<\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/seekingalpha.com\/article\/4635634-week-in-review-hasten-signs-325-million-deal-for-china-rights-to-pcsk9-cholesterol-therapy?source=feed_all_articles\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering cholesterol from US-based LIB Therapeutics. Lerodalcibep is a next-gen PCSK9 inhibitor that may overcome the limitations of current low-density lipoprotein products for patients at high-risk for cardiovascular disease. In a global Phase III [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":62065,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"gallery","meta":{"footnotes":""},"categories":[236],"tags":[83],"class_list":["post-62064","post","type-post","status-publish","format-gallery","has-post-thumbnail","hentry","category-news","tag-featured","post_format-post-format-gallery"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Hasten&#039;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=62064\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hasten&#039;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=62064\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-17T12:41:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-17T12:41:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/1694954498_image_1426271120.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"864\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=62064#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=62064\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Hasten&#8217;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy\",\"datePublished\":\"2023-09-17T12:41:35+00:00\",\"dateModified\":\"2023-09-17T12:41:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=62064\"},\"wordCount\":1015,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=62064#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=62064\",\"url\":\"https:\/\/ifintechworld.com\/?p=62064\",\"name\":\"Hasten's $325M Deal For China Rights To PCSK9 Cholesterol Therapy | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-09-17T12:41:35+00:00\",\"dateModified\":\"2023-09-17T12:41:40+00:00\",\"description\":\"Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=62064#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=62064\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=62064#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hasten&#8217;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hasten's $325M Deal For China Rights To PCSK9 Cholesterol Therapy | iFintechWorld","description":"Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=62064","og_locale":"en_US","og_type":"article","og_title":"Hasten's $325M Deal For China Rights To PCSK9 Cholesterol Therapy | iFintechWorld","og_description":"Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering","og_url":"https:\/\/ifintechworld.com\/?p=62064","og_site_name":"iFintechWorld","article_published_time":"2023-09-17T12:41:35+00:00","article_modified_time":"2023-09-17T12:41:40+00:00","og_image":[{"width":1536,"height":864,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/1694954498_image_1426271120.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=62064#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=62064"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Hasten&#8217;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy","datePublished":"2023-09-17T12:41:35+00:00","dateModified":"2023-09-17T12:41:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=62064"},"wordCount":1015,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=62064#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=62064","url":"https:\/\/ifintechworld.com\/?p=62064","name":"Hasten's $325M Deal For China Rights To PCSK9 Cholesterol Therapy | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-09-17T12:41:35+00:00","dateModified":"2023-09-17T12:41:40+00:00","description":"Deals and Financings Shanghai Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor aimed at lowering","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=62064#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=62064"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=62064#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Hasten&#8217;s $325M Deal For China Rights To PCSK9 Cholesterol Therapy"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/62064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62064"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/62064\/revisions"}],"predecessor-version":[{"id":62066,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/62064\/revisions\/62066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/62065"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}